Clinical trial · Interventional
DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma
Safety and Therapeutic Efficacy of DC Vaccine Combined With Cytokine-induced Killer Cells in Patients With Renal Cell Carcinoma: a Phase I/II Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this Phase I/II study is to evaluate the safety and efficacy of dendritic cells (DC) vaccine combined with cytokine-induced killer (CIK) cells in patients with renal cell carcinoma. Experimental recombinant adenovirus-transfected DC, which engineered to express MUC1 and Survivin are used for DC-based immunotherapy. Based on the results of our previously performed preclinical study with DC vaccine combined with CIK cells, the investigators plan to perform the clinical trial.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| adenovirus-transfected DC + CIK | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- adenovirus-transfected DC + CIK
- description
- adenovirus-transfected autologous DC vaccine plus CIK cells
- interventionNames
- Biological: adenovirus-transfected DC + CIK
Primary outcomes (1)
- measure
- objective tumor response (CR+PR) as measured by RECIST criteria
- timeFrame
- 4 weeks after DC/CIK treatment
Secondary outcomes (1)
- measure
- number of participants with adverse events
- timeFrame
- 3 days within DC/CIK treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \>18 years at time of consent * Histopathologically confirmed diagnosis of renal cell carcinoma * Received standardized treatment of renal cell carcinoma * Interval between the last standardized treatment and DC/CIK treatment ≥ 4weeks * KPS (Karnofsky performance scale) \>60 * Patient's written informed consent * Predicted survival \>3 months * No severe viral or bacterial infections Exclusion Criteria: * Receiving chemotherapy, radiotherapy or other therapy * Patients with other malignancies and infectious diseases * Pregnant and breast-feeding patient * Currently participating in another clinical trial * Unfit for participating in this clinical trial in investigators' opinions
References
Publications (1)
- DERIVEDWang D, Zhang B, Gao H, Ding G, Wu Q, Zhang J, Liao L, Chen H. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer. 2014 Apr 10;14:251. doi: 10.1186/1471-2407-14-251. PMID 24720900